Abstract:Abstract Background Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, demonstrated superior efficacy compared with placebo (PBO) in the induction and maintenance of patients with moderately to severely active ulcerative colitis (UC) in the INSPIRE and COMMAND studies. Here, we evaluated whether RZB was an effective induction and maintenance therapy based on the number (0, 1, ≥ 2) and types of prior advanced therapies (ATs). Methods Eligible patients with an Adapted Mayo Score of 5-9 points and endoscopic subscore of 2-3 (confirmed by central reading) were randomised 2:1 (intravenous [IV] RZB 1200 mg [RZB1200] or PBO) for 12 weeks (wks) in the phase 3 induction substudy of INSPIRE. Clinical responders (per Adapted Mayo Score) to RZB IV treatment in phase 2b and phase 3 induction were randomised 1:1:1 (subcutaneous [SC] RZB 180 mg (RZB180), SC RZB 360 mg (RZB360), or withdrawn to PBO [withdrawal, WD]) for 52 wks in COMMAND. Efficacy and safety outcomes were assessed at induction wk 12 and maintenance wk 52 in patients who were non-advanced therapy-inadequate responders (non-AT-IR), had 1 or ≥ 2 AT failures, and among patients previously treated with tumor necrosis factor inhibitors, vedolizumab, or Janus kinase inhibitors. Results Proportions of AT-IR patients were similar across treatment groups for the induction (RZB1200 51.2% [333/650]; PBO 52.3% [170/325]) and maintenance studies (RZB180: 74.9% [134/179]; RZB360: 74.7% [139/186]; PBO [WD] 75.4% [138/183]). Significantly greater proportions of patients receiving RZB achieved the primary endpoint of clinical remission per Adapted Mayo Score at wk 12 vs PBO in the non-AT-IR and AT-IR subgroups (RZB1200: 29.7%, 11.4% vs PBO: 8.4%, 4.3%, respectively); consistent results were observed at wk 52 in patients treated with either RZB maintenance dose vs PBO (RZB180: 50.9%, 36.6%; RZB360: 61.7%, 29.5%; vs PBO [WD] 31.1%, 23.2%, respectively) (P ≤ .05, Fig. 1-2). Regardless of the number of prior AT failures or class of prior therapy, numerically higher proportions of patients treated with RZB achieved clinical remission, clinical response, endoscopic improvement, and histologic endoscopic mucosal improvement at wk 12 of induction and wk 52 of maintenance. Rates of treatment-emergent adverse events were similar among subgroups in induction and maintenance. Conclusion RZB induction and maintenance therapy was effective and well-tolerated in patients with moderately to severely active UC regardless of a patient’s prior experience with advanced therapies. Numerically higher efficacy was observed in non-AT-IR compared to AT-IR subgroups.

Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response

Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study

Case report: Exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series

An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria

Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase 2b multinational, randomised, double-blind, placebo-controlled ARROYO trial

Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial

Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

Bruton's tyrosine kinase inhibition for the treatment of allergic disorders

P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

Sustained Improvement in UAS7 After 16-Week Treatment With Tezepelumab in Biologic-Naïve Adults with CSU: Results of the Phase 2b INCEPTION Study

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis